SL-28 / Second Life Therapeutics - LARVOL DELTA

Early clinical activity of SL-28, representing a new class of allogeneic leukocyte therapy, in biologically distinct advanced solid tumors: an interim analysis (ESMO 2026) - No abstract available

Clinical • Metastases • Oncology • Solid Tumor

SL-28 for Advanced Solid Tumours (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: Second Life Therapeutics | Not yet recruiting ➔ Recruiting | Initiation date: Feb 2026 ➔ Jul 2026

Enrollment open • Trial initiation date • Bladder Cancer • Breast Cancer • Colorectal Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genetic Disorders • Genito-urinary Cancer • Head and Neck Cancer • Hormone Receptor Positive Breast Cancer • Kidney Cancer • Liver Cancer • Lung Adenocarcinoma • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Skin Cancer • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

SL-28 for Advanced Solid Tumours (clinicaltrials.gov) - P1/2 | N=60 | Not yet recruiting | Sponsor: Second Life Therapeutics

New P1/2 trial • Bladder Cancer • Breast Cancer • Colorectal Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genetic Disorders • Genito-urinary Cancer • Head and Neck Cancer • Hormone Receptor Positive Breast Cancer • Kidney Cancer • Liver Cancer • Lung Adenocarcinoma • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Skin Cancer • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck